Published in J Urol on September 11, 2014
Epidemiology of Diabetes Interventions and Complications (EDIC) | NCT00360893
Diabetes Control and Complications Trial (DCCT) | NCT00360815
Diabetes, prostate cancer screening and risk of low- and high-grade prostate cancer: an 11 year historical population follow-up study of more than 1 million men. Diabetologia (2016) 0.76
Impact of poor glycemic control of type 2 diabetes mellitus on serum prostate-specific antigen concentrations in men. Prostate Int (2017) 0.75
Pretreatment glycemic control status is an independent prognostic factor for cervical cancer patients receiving neoadjuvant chemotherapy for locally advanced disease. BMC Cancer (2017) 0.75
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med (1993) 102.56
Cancer statistics, 2013. CA Cancer J Clin (2013) 84.72
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med (2005) 27.77
Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med (2008) 8.14
Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA (2002) 6.61
A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care (1994) 5.02
Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology (1991) 4.62
Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA (2007) 3.25
A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev (2006) 3.13
Impact of common medications on serum total prostate-specific antigen levels: analysis of the National Health and Nutrition Examination Survey. J Clin Oncol (2010) 3.13
Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care (2005) 2.52
The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst (2008) 2.46
Why does diabetes offer protective effects against prostate cancer? The possible role of its microvascular complications. Med Hypotheses (2009) 2.05
The association of body mass index and prostate-specific antigen in a population-based study. Cancer (2005) 1.85
Obesity is negatively associated with prostate-specific antigen in U.S. men, 2001-2004. Cancer Epidemiol Biomarkers Prev (2006) 1.65
The effects of type 2 diabetes and hypertension on changes in serum prostate specific antigen levels: results from the Olmsted County study. Urology (2010) 1.54
Prostate-specific antigen values in diabetic and nondiabetic US men, 2001-2002. Am J Epidemiol (2006) 1.43
Statin drugs, serum cholesterol, and prostate-specific antigen in the National Health and Nutrition Examination Survey 2001-2004. Cancer Causes Control (2010) 1.29
Association of diabetes and body mass index with levels of prostate-specific antigen: implications for correction of prostate-specific antigen cutoff values? Cancer Epidemiol Biomarkers Prev (2009) 1.25
Serum prostate-specific antigen levels in men with type 2 diabetes. Diabetes Care (2008) 1.12
Type 2 diabetes mellitus, glycemic control, and cancer risk. Eur J Cancer Prev (2014) 1.07
Obesity and screening PSA levels among men undergoing an annual physical exam. Prostate (2008) 1.04
Prostate-specific antigen testing in older men in the USA: data from the behavioral risk factor surveillance system. BJU Int (2012) 1.03
Association between prostate-specific antigen and leptin, adiponectin, HbA1c or C-peptide among African-American and Caucasian men. Prostate Cancer Prostatic Dis (2007) 1.00
Diabetes mellitus and prostate cancer risk of different grade or stage: a systematic review and meta-analysis. Diabetes Res Clin Pract (2013) 0.98
Diabetes mellitus and prostate cancer risk; a nationwide case-control study within PCBaSe Sweden. Cancer Epidemiol Biomarkers Prev (2013) 0.96
Serum glucose and fructosamine in relation to risk of cancer. PLoS One (2013) 0.85
Relationship between changes in haemoglobin A1C and prostate-specific antigen in healthy men. Eur J Cancer (2010) 0.79
Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med (2011) 7.42
Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes. Diabetes (2009) 3.16
Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care (2006) 2.64
Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial--revisited. Diabetes (2008) 2.60
Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes. N Engl J Med (2017) 2.56
Satisfaction with information used to choose prostate cancer treatment. J Urol (2013) 2.06
The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care (2014) 2.04
Sexual dysfunction in women with type 1 diabetes: long-term findings from the DCCT/ EDIC study cohort. Diabetes Care (2009) 1.87
Evaluating the role of epigenetic histone modifications in the metabolic memory of type 1 diabetes. Diabetes (2014) 1.81
New susceptibility loci associated with kidney disease in type 1 diabetes. PLoS Genet (2012) 1.79
Follow-up analysis of genome-wide association data identifies novel loci for type 1 diabetes. Diabetes (2008) 1.56
Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care (2014) 1.42
Update on cardiovascular outcomes at 30 years of the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care (2014) 1.42
Variation in SLC19A3 and Protection From Microvascular Damage in Type 1 Diabetes. Diabetes (2015) 1.40
Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes Care (2013) 1.39
Relationship of glycated albumin to blood glucose and HbA1c values and to retinopathy, nephropathy, and cardiovascular outcomes in the DCCT/EDIC study. Diabetes (2013) 1.37
Multiple variants in vascular endothelial growth factor (VEGFA) are risk factors for time to severe retinopathy in type 1 diabetes: the DCCT/EDIC genetics study. Diabetes (2007) 1.34
Genetic variation at the ACE gene is associated with persistent microalbuminuria and severe nephropathy in type 1 diabetes: the DCCT/EDIC Genetics Study. Diabetes (2005) 1.34
Common genetic determinants of intraocular pressure and primary open-angle glaucoma. PLoS Genet (2012) 1.33
Diabetic retinopathy and other ocular findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care (2014) 1.33
Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions. Diabetes (2013) 1.31
Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy. Kidney Int (2003) 1.30
BR-squared: a practical solution to the winner's curse in genome-wide scans. Hum Genet (2011) 1.28
Common genetic variation near the phospholamban gene is associated with cardiac repolarisation: meta-analysis of three genome-wide association studies. PLoS One (2009) 1.28
Myocardial structure, function, and scar in patients with type 1 diabetes mellitus. Circulation (2011) 1.20
DCCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history. Curr Diab Rep (2010) 1.18
Kidney disease and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care (2014) 1.15
Immune complexes containing modified lipoproteins are related to the progression of internal carotid intima-media thickness in patients with type 1 diabetes. Atherosclerosis (2006) 1.15
Proatherogenic and proinflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL. Clin Immunol (2002) 1.13
Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes (2013) 1.11
Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial. Diabetes Care (2017) 1.11
The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: summary and future directions. Diabetes Care (2014) 1.07
The long-term effects of type 1 diabetes treatment and complications on health-related quality of life: a 23-year follow-up of the Diabetes Control and Complications/Epidemiology of Diabetes Interventions and Complications cohort. Diabetes Care (2013) 1.07
Vibration perception threshold as a measure of distal symmetrical peripheral neuropathy in type 1 diabetes: results from the DCCT/EDIC study. Diabetes Care (2010) 1.05
Skin advanced glycation end products glucosepane and methylglyoxal hydroimidazolone are independently associated with long-term microvascular complication progression of type 1 diabetes. Diabetes (2014) 1.01
Meta-analysis of genome-wide association studies in five cohorts reveals common variants in RBFOX1, a regulator of tissue-specific splicing, associated with refractive error. Hum Mol Genet (2013) 1.01
Association between cardiovascular autonomic neuropathy and left ventricular dysfunction: DCCT/EDIC study (Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications). J Am Coll Cardiol (2012) 1.00
Clinical and technical factors associated with skin intrinsic fluorescence in subjects with type 1 diabetes from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Technol Ther (2013) 1.00
Nuclear magnetic resonance-determined lipoprotein subclass profile in the DCCT/EDIC cohort: associations with carotid intima-media thickness. Diabet Med (2006) 0.98
GWAS identifies an NAT2 acetylator status tag single nucleotide polymorphism to be a major locus for skin fluorescence. Diabetologia (2014) 0.97
SIU/ICUD Consultation on Urethral Strictures: Posterior urethral stenosis after treatment of prostate cancer. Urology (2013) 0.97
High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes. Nephrol Dial Transplant (2011) 0.97
Effects of prior intensive versus conventional therapy and history of glycemia on cardiac function in type 1 diabetes in the DCCT/EDIC. Diabetes (2013) 0.96
Autoimmune response to advanced glycosylation end-products of human LDL. J Lipid Res (2002) 0.95
Use and outcomes of extended antibiotic prophylaxis in urological cancer surgery. J Urol (2014) 0.94
Intensive diabetes therapy and ocular surgery in type 1 diabetes. N Engl J Med (2015) 0.94
Advanced glycation end-products and methionine sulphoxide in skin collagen of patients with type 1 diabetes. Diabetologia (2006) 0.94
The association of previously reported polymorphisms for microvascular complications in a meta-analysis of diabetic retinopathy. Hum Genet (2014) 0.93
Apolipoprotein C-III protein concentrations and gene polymorphisms in Type 1 diabetes: associations with microvascular disease complications in the DCCT/EDIC cohort. J Diabetes Complications (2005) 0.92
Comparison of urinary albumin-creatinine ratio and albumin excretion rate in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study. Clin J Am Soc Nephrol (2010) 0.91
The association of skin intrinsic fluorescence with type 1 diabetes complications in the DCCT/EDIC study. Diabetes Care (2013) 0.91
Haptoglobin genotype and the rate of renal function decline in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes (2013) 0.88
Cross-sectional associations of C-reactive protein with vascular risk factors and vascular complications in the DCCT/EDIC cohort. J Diabetes Complications (2008) 0.88
Oxidized LDL immune complexes and coronary artery calcification in type 1 diabetes. Atherosclerosis (2010) 0.86
LDL composition in E2/2 subjects and LDL distribution by Apo E genotype in type 1 diabetes. Atherosclerosis (2006) 0.86
Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes. Cardiovasc Diabetol (2015) 0.85
Validity of self-report in type 1 diabetic subjects for laser treatment of retinopathy. Ophthalmology (2013) 0.85
Epigenomic profiling reveals an association between persistence of DNA methylation and metabolic memory in the DCCT/EDIC type 1 diabetes cohort. Proc Natl Acad Sci U S A (2016) 0.84
Pilot genome-wide association search identifies potential loci for risk of erectile dysfunction in type 1 diabetes using the DCCT/EDIC study cohort. J Urol (2012) 0.84
Cardiovascular autonomic neuropathy, erectile dysfunction and lower urinary tract symptoms in men with type 1 diabetes: findings from the DCCT/EDIC. J Urol (2015) 0.83
Decreased plasma levels of select very long chain ceramide species are associated with the development of nephropathy in type 1 diabetes. Metabolism (2014) 0.83
Effect of glycemic treatment and microvascular complications on menopause in women with type 1 diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort. Diabetes Care (2013) 0.82
Caffeine Consumption Contributes to Skin Intrinsic Fluorescence in Type 1 Diabetes. Diabetes Technol Ther (2015) 0.81
Oxidized LDL and AGE-LDL in circulating immune complexes strongly predict progression of carotid artery IMT in type 1 diabetes. Atherosclerosis (2013) 0.81
Skin collagen fluorophore LW-1 versus skin fluorescence as markers for the long-term progression of subclinical macrovascular disease in type 1 diabetes. Cardiovasc Diabetol (2016) 0.81
Nuclear magnetic resonance-determined lipoprotein subclasses and carotid intima-media thickness in type 1 diabetes. Atherosclerosis (2015) 0.81
Apolipoprotein C-III protein concentrations and gene polymorphisms in type 1 diabetes: associations with lipoprotein subclasses. Metabolism (2004) 0.80
Paraoxonase-3 is depleted from the high-density lipoproteins of autoimmune disease patients with subclinical atherosclerosis. J Proteome Res (2015) 0.79
Plasma total homocysteine and carotid intima-media thickness in type 1 diabetes: a prospective study. Atherosclerosis (2014) 0.79
Genome-wide meta-analysis of myopia and hyperopia provides evidence for replication of 11 loci. PLoS One (2014) 0.79
Association of Cardiovascular Risk Factors and Myocardial Fibrosis With Early Cardiac Dysfunction in Type 1 Diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Care (2016) 0.78
LDL-containing immune complexes in the DCCT/EDIC cohort: associations with lipoprotein subclasses. J Diabetes Complications (2010) 0.78
Relation between carotid intima-media thickness and left ventricular mass in type 1 diabetes mellitus (from the Epidemiology of Diabetes Interventions and Complications [EDIC] Study). Am J Cardiol (2012) 0.78
Plasma Prekallikrein Is Associated With Carotid Intima-Media Thickness in Type 1 Diabetes. Diabetes (2015) 0.78
Glycemic Control and Urinary Tract Infections in Women with Type 1 Diabetes: Results from the DCCT/EDIC. J Urol (2016) 0.78
The associations of apolipoprotein E and angiotensin-converting enzyme polymorphisms and cognitive function in Type 1 diabetes based on an 18-year follow-up of the DCCT cohort. Diabet Med (2010) 0.77
Relief of Urinary Symptom Burden after Primary Prostate Cancer Treatment. J Urol (2016) 0.77
Associations between intensive diabetes therapy and NMR-determined lipoprotein subclass profiles in type 1 diabetes. J Lipid Res (2015) 0.76
Self-reported autoimmune disease by sex in the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study. Diabetes Care (2014) 0.76
Cardiovascular Autonomic Neuropathy and Cardiovascular Outcomes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes Care (2016) 0.75
Testosterone and cardiac mass and function in men with type 1 diabetes in the Epidemiology of Diabetes Interventions and Complications Study (EDIC). Clin Endocrinol (Oxf) (2016) 0.75
New Locus for Skin Intrinsic Fluorescence in Type 1 Diabetes Also Associated With Blood and Skin Glycated Proteins. Diabetes (2016) 0.75
Haptoglobin 2-2 genotype and the risk of coronary artery disease in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). J Diabetes Complications (2016) 0.75
Lymphoblastoid Cell Lines as a Tool to Study Inter-Individual Differences in the Response to Glucose. PLoS One (2016) 0.75
Significance of Epicardial and Intrathoracic Adipose Tissue Volume among Type 1 Diabetes Patients in the DCCT/EDIC: A Pilot Study. PLoS One (2016) 0.75